Balanitis

Summary

Balanitis (MONDO:0006672) is a disease and 2 clinical trials. Top therapeutic interventions include acetaminophen. A subtype of penile disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	balanitis
Mondo ID	MONDO:0006672
EFO	EFO:1000833
MeSH	D001446
DOID	DOID:13033
ICD-10-CM	N48.1
NCIT	C26705
SNOMED CT	44882003
UMLS	C0004690
MedGen	14020
MedDRA	10004073
Is cancer (heuristic)	no

Also known as: balanitis · glans penis inflammation · inflammation of glans penis

Disease family

This is a subtype of penile disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › penile disorder › balanitis

Related subtypes (6): erectile dysfunction, leukoplakia of penis, penile neoplasm, phimosis, posthitis, vascular disorder of penis

Subtypes (3): balanoposthitis, balanitis xerotica obliterans, anaerobic balanitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04646967	PHASE2	COMPLETED	An Evaluation of Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision
NCT02973958	PHASE1	COMPLETED	Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACETAMINOPHEN	4	2